Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Nurix Therapeutics's accounts receivables for the quarter that ended in Feb. 2024 was $0.00 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Nurix Therapeutics's Days Sales Outstanding for the quarter that ended in Feb. 2024 was 0.00.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Nurix Therapeutics's Net-Net Working Capital per share for the quarter that ended in Feb. 2024 was $2.04.
Nurix Therapeutics Accounts Receivable Historical Data
The historical data trend for Nurix Therapeutics's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Nurix Therapeutics's Days Sales Outstanding for the quarter that ended in Feb. 2024 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Nurix Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Nurix Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Feb. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Nurix Therapeutics Accounts Receivable Related Terms
Thank you for viewing the detailed overview of Nurix Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Nurix Therapeutics (Nurix Therapeutics) Business Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NRIX has been successfully added to your 